5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05187546 (ClinicalTrials.gov) | February 2022 | 23/11/2021 | Test-retest Study With [18F]PI-2620 in PSP-RS and NDC | An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC) | Progressive Supranuclear Palsy | Drug: [18F]-PI2620 | Life Molecular Imaging GmbH | NULL | Recruiting | 50 Years | 80 Years | All | 15 | Phase 1 | Germany |
| 2 | NCT04715750 (ClinicalTrials.gov) | November 12, 2020 | 11/12/2020 | Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity | An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity | Alzheimer Disease;Progressive Supranuclear Palsy | Drug: [18F]-PI2620 | Life Molecular Imaging GmbH | Life Molecular Imaging SA | Recruiting | 50 Years | 80 Years | All | 10 | Phase 1 | Germany |